Close
Novotech
Jabsco PureFlo 21 Single Use

Press Ganey Report on Health Care Safety Culture Prior to and During the COVID-19 Pandemic Finds Downward Trend Continues

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

Press Ganey released its newest research brief, Reverse the Trend: Improving Safety Culture in the COVID-19 Era. Analyses of national safety culture data and trends prior to and during the COVID-19 pandemic reveal that after a period of modest improvement from 2017 to 2019, scores for most safety culture themes declined in 2020. The report serves as an urgent call to action as caregivers’ perceptions of safety culture are a leading indicator of future safety outcomes. The report provides key takeaways and critical, high-impact strategies to improve safety culture and reverse the downward trend.

Key findings include the following.

  • Scores for most safety culture themes declined in 2020, particularly in the categories of Prevention & Reporting and Resources & Teamwork. Scores for Pride & Reputation remained steady over time.
  • Scores reflecting staffing, job stress, and both caregiver and patient safety saw the greatest drop-off in 2020.
  • Leaders should focus on safety culture fundamentals that yield significant return such as Leaders’ Messaging on Safety, outlined in the report.

“The magnitude of the COVID-19 outbreak and the rapidly evolving risks and needs left health systems overburdened and vulnerable to safety culture deterioration, which has the potential to impact safety outcomes,” said Dr. Tejal Gandhi, Chief Safety & Transformation Officer, Press Ganey. “Fortunately, the downward trend we’ve identified can be reversed. High reliability principles are the foundation of a strong safety culture and help hardwire processes and behaviors that prepare an organization to respond effectively to new challenges. As the United States cautiously moves out of crisis mode, reinvigorating safety culture should be top of mind at all health systems for the benefit of all patients and caregivers.”

In November 2019, Press Ganey announced the launch of its Safety 2025 initiative, with the goal of an 80% reduction in preventable harm to patients and caregivers by 2025. Since then, more than 300 acute care and 1,100 non-acute care facilities have joined the movement.

“As further demonstration of our organization-wide commitment to advancing the industry to Zero Harm, I am pleased to announce that we are opening access to the next three sessions of our signature Safety 2025 High Reliability Learning Series to all health care organizations,” said Nell Buhlman, President and COO, Press Ganey. “This collaborative forum facilitates peer-to-peer learning and sharing of best practices and proven strategies to enhance health care safety culture and high reliability processes. We invite all interested parties to register now for the first session.”

About Press Ganey

Press Ganey pioneered the health care performance improvement movement 35 years ago. Today Press Ganey offers an integrated suite of solutions that enable enterprise transformation across the patient journey. Delivered through a cutting-edge digital platform built on a foundation of data security, Press Ganey solutions address safety, clinical excellence, patient experience, and workforce engagement. The company works with more than 41,000 health care facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality, and experience of care.

 

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »